title: The effect of schedule, protein binding and growth factors on the activity of suramin.
abstract: Suramin has been shown to have antiproliferative activity, either by blocking the binding of growth factors to their receptors or by inhibiting critical cellular enzymes. In 6 different cell lines from 5 tumour types (MCF-7, MCF-7/ADRR, PC3, HT-29, UM-SCC-11B and SW-1573/IR500), we studied the effect of scheduling of suramin, of FCS and of human serum albumin (HSA), of epidermal growth factor (EGF) and of the addition of growth factors in serum-free medium on the activity of suramin. The concentration of suramin which gave 50% growth inhibition (IC50) varied from 45 microM in SW-1573/IR500 to 153 microM in PC3 cells grown in medium supplemented with 5% FCS, after 6 days of continuous exposure. Exposure for more than 4 days did not enhance the sensitivity to suramin, except in PC3. At exposure to suramin for 1 day followed by 5 days recovery, high IC50 values (greater than 0.5 mM) were observed in MCF-7 cells. In medium with 1% and 0.5% FCS these values were 3 to 8 and 14 to 26 times lower respectively. Addition of HSA increased the IC50 in PC3 and MCF-7 cells. Suramin binding to protein was dependent on the concentration of protein and of suramin. Excess of EGF in medium with different FCS concentrations did not change the IC50 values of suramin in PC3 and MCF-7 cells. Addition of EGF, fibroblast growth factor or platelet-derived growth factor in PC3 cells cultured in serum-free medium did not increase the IC50 values. Suramin was active against these 6 cell lines at clinically achievable concentrations. This activity varied depending on the cell line, exposure time and suramin concentration. The most significant factor interfering with sensitivity to suramin was the amount of protein present in the culture medium.
authors.affiliation: Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Lopez Lopez
authors.forename: G J
authors.initials: GJ
authors.lastname: Peters
authors.forename: A C
authors.initials: AC
authors.lastname: van Loenen
authors.forename: P E
authors.initials: PE
authors.lastname: Pizao
authors.forename: R E
authors.initials: RE
authors.lastname: van Rijswijk
authors.forename: J
authors.initials: J
authors.lastname: Wagstaff
authors.forename: H M
authors.initials: HM
authors.lastname: Pinedo
mesh_terms: D001769:Blood; D001798:Blood Proteins / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects*; D002460:Cell Line; D016895:Culture Media, Serum-Free; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism / Q000494:pharmacology; D013498:Suramin / Q000378:metabolism* / Q000494:pharmacology*; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D001798:Blood Proteins; D016895:Culture Media, Serum-Free; D006133:Growth Substances; D012709:Serum Albumin; D013498:Suramin; D004815:Epidermal Growth Factor